Steve Whitaker

Phosphodiesterase-5 Inhibitor in Eisenmenger Syndrome

Tadalafil Therapy for Pulmonary Arterial Hypertension

Efficacy and Tolerability of Tadalafil for Treatment of Erectile Dysfunction in Men Taking Serotonin Reuptake Inhibitors

Current oral treatments for erectile dysfunction

Emerging Pharmacologic Approaches for the Treatment of Lower Urinary Tract Disorders

Evaluation of the Efficacy and Safety of Once-a-Day Dosing of Tadalafil 5mg and 10mg in the Treatment of Erectile Dysfunction: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Update on Phosphodiesterase (PDE) Isoenzymes as Pharmacologic Targets in Urology: Present and Future

Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class

Cyclic Nucleotide Phosphodiesterases: Molecular Regulation to Clinical Use

Pharmacokinetic Interaction Between Tadalafil and Bosentan in Healthy Male Subjects

Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension

Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis

Organic Causes of Erectile Dysfunction in Men Under 40

Efficacy and Safety of Tadalafil Once Daily in the Treatment of Men With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia: Results of an International Randomized, Double-Blind, Placebo-Controlled Trial

Image-guided cancer surgery using near-infrared fluorescence

cGMP-Dependent Protein Kinases and cGMP Phosphodiesterases in Nitric Oxide and cGMP Action

Tadalafil Improved Erectile Function at Twenty‐Four and Thirty‐Six Hours After Dosing in Men With Erectile Dysfunction: US Trial

Physiology and Pathophysiology of Purinergic Neurotransmission

Return-to-work interventions integrated into cancer care: a systematic review

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

Chronic Treatment with Tadalafil Improves Endothelial Function in Men with Increased Cardiovascular Risk

Treatment of Erectile Dysfunction in Patients with Cardiovascular Disease

Time course of the interaction between tadalafil and nitrates

The Role of Nitric Oxide in Erectile Dysfunction: Implications for Medical Therapy

Phosphodiesterase 5 Inhibitors for Erectile Dysfunction

Recent Fascinating Aspects of the CuAAC Click Reaction

Sexual Function after Surgery for Prostate or Bladder Cancer

Diversity‐Oriented Syntheses by Combining CuAAC and Stereoselective INCIC Reactions with Peptides

ACC/AHA 2008 Guidelines for the Management of Adults With Congenital Heart Disease: Executive Summary

Diversity Oriented Clicking (DOC): Divergent Synthesis of SuFExable Pharmacophores from 2‐Substituted‐Alkynyl‐1‐Sulfonyl Fluoride (SASF) Hubs

The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension

Rehabilitation bei Patienten mit Prostatakarzinom

Ca²⁺Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase

Diversity Oriented Clicking (DOC): Divergent Synthesis of SuFExable Pharmacophores from 2‐Substituted‐Alkynyl‐1‐Sulfonyl Fluoride (SASF) Hubs

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

TADALAFIL IN THE TREATMENT OF ERECTILE DYSFUNCTION FOLLOWING BILATERAL NERVE SPARING RADICAL RETROPUBIC PROSTATECTOMY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED TRIAL

Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses

Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses